Clinical trial
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating…
NCT00006045 · Facet Biotech, Industry · Unknown status
Key facts
| NCT number | NCT00006045 |
|---|---|
| Title | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia |
| Official title | Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patients With Refractory or First-Relapsed Acute… |
| Lead sponsor | Facet Biotech, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | lintuzumab, cytarabine, etoposide, mitoxantrone hydrochloride |
| Start date | Mar 1, 2000 |
| First posted | Apr 13, 2004 |
| Last update posted | Nov 6, 2013 |
| Countries | Belgium, Canada, France, Germany, Netherlands, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: